MIRA INFORM REPORT
|
Report No. :
|
502001
|
|
Report Date :
|
10.04.2018
|
|
Name :
|
SABINSA CORPORATION
|
|
|
|
|
Registered Office :
|
East Windsor, NJ, USA
|
|
|
|
|
Country :
|
United States
|
|
|
|
|
Financials (as on) :
|
2016 [Summarized]
|
|
|
|
|
Date of Incorporation :
|
03.08.1983
|
|
|
|
|
Legal Form :
|
Domestic Profit Corporation
|
|
|
|
|
Line of Business :
|
Manufactures, supplies, and markets herbal extracts, cosmeceuticals,
minerals, dietary supplements, and specialty fine chemicals for nutritional, cosmetic,
pharmaceutical, and food industries worldwide.
|
|
|
|
|
No. of Employees :
|
63
|
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
Credit Rating
|
Explanation
|
Rating Comments
|
|
A
|
Acceptable Risk
|
Business dealings permissible with
moderate risk of default
|
|
Status :
|
Good
|
|
|
|
|
Payment Behaviour :
|
Regular
|
|
|
|
|
Litigation :
|
Clear
|
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name
|
Previous
Rating
(30.09.2017)
|
Current Rating
(31.12.2017)
|
|
United States
|
A1
|
A1
|
|
Risk Category
|
ECGC
Classification
|
|
Insignificant
|
A1
|
|
Low Risk
|
A2
|
|
Moderately Low Risk
|
B1
|
|
Moderate Risk
|
B2
|
|
Moderately High Risk
|
C1
|
|
High Risk
|
C2
|
|
Very High Risk
|
D
|
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with
a per capita GDP of $59,500. US firms are at or near the forefront in
technological advances, especially in computers, pharmaceuticals, and medical, aerospace,
and military equipment; however, their advantage has narrowed since the end of
World War II. Based on a comparison of GDP measured at purchasing power parity
conversion rates, the US economy in 2014, having stood as the largest in the
world for more than a century, slipped into second place behind China, which
has more than tripled the US growth rate for each year of the past four
decades.
In the US, private individuals and business firms make most of the
decisions, and the federal and state governments buy needed goods and services
predominantly in the private marketplace. US business firms enjoy greater
flexibility than their counterparts in Western Europe and Japan in decisions to
expand capital plant, to lay off surplus workers, and to develop new products.
At the same time, businesses face higher barriers to enter their rivals' home
markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for lower-income
families, inadequate investment in deteriorating infrastructure, rapidly rising
medical and pension costs of an aging population, energy shortages, and sizable
current account and budget deficits.
The onrush of technology has been a driving factor in the gradual
development of a "two-tier" labor market in which those at the bottom
lack the education and the professional/technical skills of those at the top
and, more and more, fail to get comparable pay raises, health insurance coverage,
and other benefits. But the globalization of trade, and especially the rise of
low-wage producers such as China, has put additional downward pressure on wages
and upward pressure on the return to capital. Since 1975, practically all the
gains in household income have gone to the top 20% of households. Since 1996,
dividends and capital gains have grown faster than wages or any other category
of after-tax income.
Imported oil accounts for more than 50% of US consumption and oil has a
major impact on the overall health of the economy. Crude oil prices doubled
between 2001 and 2006, the year home prices peaked; higher gasoline prices ate
into consumers' budgets and many individuals fell behind in their mortgage
payments. Oil prices climbed another 50% between 2006 and 2008, and bank
foreclosures more than doubled in the same period. Besides dampening the
housing market, soaring oil prices caused a drop in the value of the dollar and
a deterioration in the US merchandise trade deficit, which peaked at $840
billion in 2008. Because the US economy is energy-intensive, falling oil prices
since 2013 have alleviated many of the problems the earlier increases had
created.
The sub-prime mortgage crisis, falling home prices, investment bank
failures, tight credit, and the global economic downturn pushed the US into a
recession by mid-2008. GDP contracted until the third quarter of 2009, the
deepest and longest downturn since the Great Depression. To help stabilize
financial markets, the US Congress established a $700 billion Troubled Asset
Relief Program (TARP) in October 2008. The government used some of these funds
to purchase equity in US banks and industrial corporations, much of which had
been returned to the government by early 2011. In January 2009, Congress passed
and former President Barack OBAMA signed a bill providing an additional $787
billion fiscal stimulus to be used over 10 years - two-thirds on additional
spending and one-third on tax cuts - to create jobs and to help the economy
recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP.
In 2012, the Federal Government reduced the growth of spending and the deficit
shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a
percentage of GDP, than those of most other countries.
Wars in Iraq and Afghanistan required major shifts in national resources
from civilian to military purposes and contributed to the growth of the budget
deficit and public debt. Through FY 2018, the direct costs of the wars will
have totaled more than $1.9 trillion, according to US Government figures.
In March 2010, former President OBAMA signed into law the Patient
Protection and Affordable Care Act (ACA), a health insurance reform that was
designed to extend coverage to an additional 32 million Americans by 2016,
through private health insurance for the general population and Medicaid for
the impoverished. Total spending on healthcare - public plus private - rose
from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the former president signed the DODD-FRANK Wall Street
Reform and Consumer Protection Act, a law designed to promote financial
stability by protecting consumers from financial abuses, ending taxpayer
bailouts of financial firms, dealing with troubled banks that are "too big
to fail," and improving accountability and transparency in the financial
system - in particular, by requiring certain financial derivatives to be traded
in markets that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to
purchase $85 billion per month of mortgage-backed and Treasury securities in an
effort to hold down long-term interest rates, and to keep short-term rates near
zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed
ended its purchases during the summer of 2014, after the unemployment rate
dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of
GDP. In December 2015, the Fed raised its target for the benchmark federal
funds rate by 0.25%, the first increase since the recession began. With
continued low growth, the Fed opted to raise rates several times since then,
and in December 2017, the target rate stood at 1.5%.
In December 2017, Congress passed and President Donald TRUMP signed the
Tax Cuts and Jobs Act, which, among its various provisions, reduces the
corporate tax rate from 35% to 21%; lowers the individual tax rate for those
with the highest incomes from 39.6% to 37%, and by lesser percentages for those
at lower income levels; changes many deductions and credits used to calculate
taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do
not obtain the minimum amount of health insurance required under the ACA. The
new taxes took effect on 1 January 2018; the tax cut for corporations are
permanent, but those for individuals are scheduled to expire after 2025. The
Joint Committee on Taxation (JCT) under the Congressional Budget Office
estimates that the new law will reduce tax revenues and increase the federal
deficit by about $1.45 trillion over the 2018-2027 period. This amount would
decline if economic growth were to exceed the JCT’s estimate.
|
|
Location
Facts
|
|
Government
|
Federal
|
|
Currency
|
USD
|
|
EconomicRisk
|
NIL
|
Statutory
Information
|
|
Legal
Name
|
SABINSA
CORPORATION
|
|
Trade
Name
|
SABINSA
SABINSA
CORP
|
|
ID
|
ID
|
|
ID
Details
|
0100202125
|
|
Creation
Date
|
1983
|
|
Incorporation
Date
|
08/03/1983
|
|
Legal
Address
|
East
Windsor, NJ, USA
|
|
Operative
Address
|
20 Lake Dr Hightstown, Nj, 08520-5321 United States
|
|
Telephone
|
732-777-1111
|
|
Fax
|
732-777-1443
|
|
Legal
Form
|
Domestic
Profit Corporation
|
|
E-Mail
|
info@sabinsa.com
|
|
Registered
In
|
New
Jersey (NJ)
|
|
Website
|
www.sabinsa.com
|
|
Contact
|
Jayasankar A. Nair, Chief Executive Officer Muhammed Majeed Ph.D.,
Founder
|
|
Staff
|
63
|
|
Activity
|
SIC 2 Description: Wholesale Trade - Nondurable Goods SIC 4
Description: Drugs, Proprietaries, And Sundries
|
Banks
|
|
There are not informed banks
|
|
Description
|
The company does not make its banking data public.
|
History
|
|
History
|
The company was founded in 1983 by Muhammed
Majeed, Ph.D.
|
|
Key
Developments
|
Sabinsa Corporation Presents at SupplySide West
2017, Sep-29-2017
01:45 PM Sep 26 17
Sabinsa Corporation Presents at SupplySide West
2017, Sep-29-2017 01:45 PM.
Venue: Mandalay Bay, 3950 S Las Vegas Blvd, Las
Vegas, Nevada, United States.
Speakers: Shaheen Majeed, President of Sabinsa
Worldwide. Sabinsa Corporation to Launch Promond™ Almond Protein Powder,
Give Away New Bioperine Book at SupplySide West Sep 22 17 Sabinsa
Corporation will launch Promond™, the company’s first protein powder
ingredient, at SupplySide West, September 27-28, 2017, Mandalay Bay in Las
Vegas, NV. Promond TM almond protein is a water-soluble protein sourced
from Indian variety of almonds. It has a complete amino acid profile. Those
concerned about almonds grown in California because of heavy water use in
drought conditions won’t have to worry - Promond is made from almonds
sourced in northern India. Sabinsa will be giving away a book on the
company’s patented black pepper extract, BioPerine®. While this ingredient
has been widely used to enhance the bioavailability of other nutrients as
well as for its thermo-nutrient properties, the book explores many new uses
backed by research findings.
Sabinsa and Chemill Reach Licensing Agreement Sep
22 16
Sabinsa Corp. and Chemill Inc. have reached an
agreement which resolves a previous lawsuit for infringement of Sabinsa’s
U.S. Patent No. 6,653,327, covering compositions and uses of
turmeric-derived tetrahydrocurcuminoids. The matter has been settled on
undisclosed terms. Chemill will respect the Patent as a due licensee.
Sabinsa’s patent covers compositional claims and also several topical and
oral applications of tetrahydrocurcuminoids noted for their high
anti-oxidant capacity.
|
|
Parent
Company
|
NA
|
Principal
Activity
|
|
General
Description
|
Sabinsa Corporation manufactures, supplies, and
markets herbal extracts, cosmeceuticals, minerals, dietary supplements, and
specialty fine chemicals for nutritional, cosmetic, pharmaceutical, and
food industries worldwide.
|
|
Service/Product
Description
|
It offers natural drugs, standardized
phytoextracts, SCFE products, natural proteins, enzymes, probiotics and
synbiotics, beverage ingredients, functional nutritional blends, functional
cosmetic blends, nutritional fine chemicals, chiral drug intermediates,
nutritional fibers, minerals for nutritional use, and other products and
ingredients; and custom manufacturing and contract manufacturing services.
PRODUCTS: Natural Drugs Standardized Phyto
Extracts SCFE Products Natural Proteins Enzymes Probiotics and Synbiotics
Beverage/Liquid Dietary Supplements Cosmeceuticals Nutritional Fibers
Chiral Drug Intermediates Nutritional Fine Chemicals Specialty Fine
Chemicals Proprietary Cosmeceutical Blends Functional Nutritional Blends
Minerals for Nutritional Use AquaSol Ingredients GRAS Affirmed Ingredients
Custom Manufacturing Contract Manufacturing Product Specification Sheet
|
|
Sales
|
Wholesale
|
|
Operations
Area
|
National
and International
|
|
Imports
From
|
Dubai
and India
|
|
Export
To
|
Worldwide
|
|
Employees
|
63
employees
|
|
Payments
With Suppliers
|
Regular
|
|
Brands
|
|
Brand
|
|
|
SABINSA
|
|
|
FORSLEAN
|
|
|
CITRINK
|
|
|
COCOCIN
|
|
|
SABEET
|
|
|
|
|
|
Clients
|
|
Name
of Client
|
Country
|
Comments
|
|
ESPECIALISTAS
EN SUPLEMENTOS NATURALES APLICADOS SA DE CV
|
MEXICO
|
|
|
Noregal
Sa De Cv
|
MEXICO
|
|
|
INGREDIENTES
Y PRODUCTOS FUNCIONALES S . A S.
|
COLOMBIA
|
|
|
|
|
|
Suppliers
|
|
Supplier
Name
|
Country
|
Comments
|
|
HANBURY
FZE
|
DUBAI
|
|
|
Sami
Labs Ltd.
|
INDIA
|
|
|
Location
|
|
Headquarters
|
20 LAKE DR HIGHTSTOWN, NJ, 08520-5321 United States
|
|
Branches
|
750 Innovation Circle Payson UT 84651, USA +1 801 465 8400 +1 801
465 8600 info.utah@sabinsa.com
|
Group
Structure and Subdiary Companies
|
|
Listed at the stock exchange
|
NO
|
|
Stock
Amount:
|
500000
|
|
Shareholders
(%)
|
This is a private company. The company does not
disclose information on shareholders. The following information has been obtained
through private sources and could not be confirmed:
Major holder is Muhammed Majeed Ph.D.
|
|
Management
|
Jayasankar A. Nair, Chief Executive Officer
Muhammed Majeed Ph.D., Founder
Madhu Subramanian, President of Global Business
Expansion & Operations
N. Kalyanam Ph.D., President of R&D
Shaheen Majeed, President of Sabinsa Worldwide
Anurag Pande, Vice President Scientific Affairs
Camille Somaru, Quality Control Manager Madhu Subraminian, Vice President
of Finance
|
|
Subsidiary
Companies
|
NA
|
|
Related
Companies
|
Sabinsa Australia Pty Ltd. ABN 28 111 273 619
Level 1, Westfield Towers 100 William Street East Sydney NSW 2011,
Australia +61 2 9356 2211 +61 2 9356 2308 info.australia@sabinsa.com www.sabinsa.com.au
Sabinsa China 11F, Nanjing Investment Mansion #414
South Zhongshan Road Nanjing 210006, China +86 025 5238 9432, 5238 9433 +86
025 5238 9436
info.china@sabinsa.com www.sabinsa.com.cn
Sabinsa Europe
GmbH Monzastrasse 4 63225 Langen Germany +49 6103 270 11 11 +49 6103 270 11
27
info.europe@sabinsa.com
www.sabinsaeurope.com
Sami Labs Limited 19/1, 19/2, 1st Main 2nd Phase
Peenya Industrial Area Bangalore 560058, India +91 80 2839 7973 - 75, 78
+91 80 2837 3035 mail@samilabs.com
www.samilabs.com
SabinsaJapan
Corporation
6F, Tact4 Building 2-32-12 Minami Ikebukuro
Toshima-Ku, Tokyo 171-0022,
Japan +81 3 5979 7240 +81 3 5979 7241
info.japan@sabinsa.com www.sabinsa.co.jp
Sabinsa Korea #1610, Yeoksam Heights 642-19,
Yeoksam-Dong, Gangnam-Gu Seoul 135-981, South Korea +82 2 565 7241 +82 2
565 7242 info.korea@sabinsa.com
www.sabinsa.co.kr
Sabinsa South Africa (Pty) Ltd.
Belkev House 20 Basalt Avenue Amalgam Johannesburg
2031 Republic of South Africa +27 11 830 1459 +27 86 546 1252 info.sa@sabinsa.com
www.sabinsa.co.za
Sabinsa UAE - Dubai Hanbury FZE P.O. Box 61091
Jebel Ali Free Zone Dubai, U.A.E.
+971 4 883 8981 +971 4 883 8978 mail@hanburyfze.ae
www.hanburyfze.com
Sabinsa Vietnam 2nd Floor,
Pax Sky Building 123 Nguyen Dinh Chieu Str. Ward
6, Dist.3 Ho Chi Minh City, Vietnam +84 83 930 03 41 +84 83 930 03 42
info.vietnam@sabinsa.com
|
Financial
Information
|
|
General
Description
|
The company does not make its financial statements public. The
following information has been provided by private sources.
|
|
Year/Currency
|
2016
USD
|
|
Sales
|
34,200,000
|
|
Money
Flow
|
Normal
|
|
Import Fob Dollar
|
|
There are not Import Fob Dollar informed
|
|
|
Export Fob Dollar
|
|
There are not Export Fob Dollar informed
|
|
Legal
Filings
|
|
Description
|
NA
|
|
Judgments
|
SABINSA CORPORATION V. HERBAKRAFT, INC., et al,
No. 1:2014cv04738 - Document 75 (D.N.J. 2017) Court Description: OPINION.
Signed by Judge Robert B. Kugler on 6/27/2017. (dmr) SABINSA CORPORATION v.
OLIVE LIFESCIENCES PVT. LTD. Plaintiff: SABINSA CORPORATION Defendant:
OLIVE LIFESCIENCES PVT. LTD. Counter_claimant: OLIVE LIFESCIENCES PVT. LTD.
Counter_defendant: SABINSA CORPORATION Case Number: 1:2014cv04739 Filed:
July 30, 2014 Court: New Jersey District Court Office: Camden Office
County: XX US, Outside State Presiding Judge: Jerome B. Simandle Referring
Judge: Karen M. Williams Nature of Suit: Patent Cause of Action: 35:271
Jury Demanded By: Both
|
|
Trademarks
|
Sabinsa Corporation Trademarks
BIOPERINE
standardized extract from black pepper or long pepper
containing piperine formulated with nutritional items for use as a…
Owned by: Sabinsa Corporation
Serial Number: 85164726
GUGULIPID
natural gum extract used to treat high cholesterol
by reducing harmful serum lipids in the bloodstream
Owned by: Sabinsa Corporation
Serial Number: 85164739
FORSLEAN
Natural extract of Coleus forskohlii root sold as
an essential ingredient of dietary supplements
Owned by: Sabinsa Corporation
Serial Number: 85164775
LEANGARD
Dietary supplement
Owned by: Sabinsa Corporation
Serial Number: 85164881
RESVENOX
Dietary supplements
Owned by: Sabinsa Corporation
Serial Number: 85164907
SABIWHITE
Ultrapure tetrahydrocurcumin in the nature of a
plant extract for use as a component in cosmetics
Owned by: Sabinsa Corporation
Serial Number: 85164928
SELENIUM SELECT
non-prescription dietary supplements containing
selenium
Owned by: Sabinsa Corporation
Serial Number: 85164955
CAPSALLYL
Dietary supplement containing a botanical extract
and specifically excluding any starch or starch related ingredients
Owned by: Sabinsa Corporation
Serial Number: 85247037
CALEBINOIDS
Botanical extracts for use in making cosmetics
Owned by: Sabinsa Corporation
Serial Number: 85347349
TETRAMIN T3 COMPLEX
Nutraceuticals for use as a dietary supplement
Owned by: Sabinsa Corporation
Serial Number: 85364489
JOHARA THE SCIENCE OF COSMETICS
Cosmetics
Owned by: Sabinsa Corporation
Serial Number: 85708716
CINNASIL
Dietary supplements
Owned by: Sabinsa Corporation
Serial Number: 85708770
SILCIN
Dietary Supplements
Owned by: Sabinsa Corporation
Serial Number: 85708784
SELENOFORCE
Dietetic substances adapted for medical use,
namely, dietetic organic selenium enriched garlic substance, mineral
supplements…
Owned by: Sabinsa Corporation
Serial Number: 85709805
NILITIS WALK MORE
Dietary supplements
Owned by: Sabinsa Corporation
Serial Number: 85709850
INTEGRATED NUTRITIONAL COMPOSITES
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 85774585
MULTI RELEASE NUTRITIONAL COMPOSITES
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 85774605
POLYBOS
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 85851850
CURCUMIN C3 REDUCT
dietary and nutritional supplements containing
hydrogenated curcuminoids
Owned by: Sabinsa Corporation
Serial Number: 85887646
PTEROSIN WS
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 85921412
CLINICALLY FOCUSED NUTRITION
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 86001789
NATURE EMPOWERED BY SYNTHESIS
Chemist services
Owned by: Sabinsa Corporation
Serial Number: 86022130
D' COSMIX
Cosmetics
Owned by: Sabinsa Corporation
Serial Number: 86086912
MACUMAX
Dietary and nutritional supplements
Owned by: Sabinsa Corporation
Serial Number: 86150848
|
|
Patents Registered
|
Patents Assigned to Sabinsa Corporation
Convenient process of manufacture for
difluoromethylornithine and related compounds
Patent number: 7345196
Abstract: A process for the manufacture of
?-Difluoromethylornithine, analogs and derivatives is described from
ornithine hydrochloride or from N?-phthaloyl ornithine hydrochloride,
conversion to an alkyl ester, conversion to solid derivatives through the
formation of Schiff bases, subsequent halomethylation using suitable bases
and hydrolysis.
Type: Grant
Filed: February 10, 2006
Date of Patent: March 18, 2008
Assignee: Sabinsa Corporation
Inventors: Muhammed Majeed, Kalyanam
Nagabhushanam, Keshava Rao Rapole, Ravikrishna Chebolu
Method of preparation and use of coconut water in
mamalian tissue nourishment growth and healthy maintenance
Patent number: 7300682
Abstract: A nutritional, cosmetic and
pharmaceutical compositions containing active ingredients from the liquid
endosperm of fresh green coconuts, and a method for obtaining the active
ingredients.
Type: Grant
Filed: November 15, 2001
Date of Patent: November 27, 2007
Assignees: Sabinsa Corporation, Sami Labs Ltd.
Inventors: Muhammed Majeed, Vladimir Badmaev
Bioavailable composition of natural and synthetic
HCA
Patent number: 7063861
Abstract: The invention relates to a composition
comprising hydroxycitric acid (HCA) in combination with either one or both
of garcinol and anthocyanin, and its use as a weight-loss therapy in animal
subjects, preferably humans. The therapeutic effects for the composition
observed in murine and human studies include a reduction in total body
weight and body mass index, a reduction in body fat, an increase in lean
body mass and content of body water, and a reduction in perceived appetite
level. Another composition for use in weight-loss therapy is also described
relating to forskolin in combination with either one or both of garcinol
and anthocyanin. The anti-oxidant properties of garcinol are described as
being enhanced in the presence of HCA and anthocyanin, and the combination
of HCA, garcinol and anthocyanin is also shown to exert greater citrate
lyase inhibiting properties than either compound alone. Methods of
obtaining HCA, garcinol or anthocyanin, or a composition containing all
three compounds, are described.
Type: Grant
Filed: August 17, 2001
Date of Patent: June 20, 2006
Assignee: Sabinsa Corporation
Inventors: Muhammed Majeed, Vladimir Hadmaev
Convenient process of manufacture for
difluoromethylornithine and related compounds
Patent number: 6998502
Abstract: A process for the manufacture of
?-Difluoromethylornithine, analogs and derivatives is described from
ornithine hydrochloride or from N?-phthaloyl ornithine hydrochloride,
conversion to an alkyl ester, conversion to solid derivatives through the
formation of Schiff bases, subsequent halomethylation using suitable bases
and hydrolysis.
Type: Grant
Filed: September 5, 2002
Date of Patent: February 14, 2006
Assignee: Sabinsa Corporation
Inventors: Muhammed Majeed, Kalyanam
Nagabhushanam, Keshava Rao Rapole, Ravikrishna Chebolu
Method of increased bioavailability of nutrients and
pharmaceutical preparations with tetrahydropiperine and its analogues and
derivatives
Patent number: 6849645
Abstract: Tetrahydropiperine and analogs and
derivatives thereof, including dihydropiperine, are disclosed to enhance
the absorption and/or bioavailablity of nutrients, drugs and other organic
compounds, such as insectides.
Type: Grant
Filed: May 21, 2001
Date of Patent: February 1, 2005
Assignees: Sabinsa Corporation, Sami Labs LTD
Inventors: Muhammed Majeed, Vladimir Badmaev,
Rajinder Kumar Bammi, Subbalakshmi Prakash, Sankaran Natarajan
Process for the production of potassium hydroxy
citric acid, and compositions containing the potassium hydroxy citric acid
Patent number: 6770782
Abstract: The present invention provides a new
process for the isolation of hydroxy citric acid in the form of a potassium
salt from Garcinia fruit. The present invention also provides compositions
containing the potassium hydroxy citrate for use as appetite suppressants.
Type: Grant
Filed: May 22, 1998
Date of Patent: August 3, 2004
Assignee: Sabinsa Corporation
Inventors: Muhammed Majeed, Vladimir Badmaev,
Ramaswamy Rajendran
|
|
Renevals
|
Filing Type
Year Filed
CHANGE OF REGISTERED OFFICE - 2010
CHANGE OF REGISTERED OFFICE - 1997
CHANGE OF REGISTERED OFFICE - 1986
CHANGE OF REGISTERED AGENT - 2000
NAME CHANGE - 1997
REINSTATED -
1994
CHANGE OF AGENT AND OFFICE - 2007
CHANGE OF AGENT AND OFFICE - 1988
VOIDED FOR FAILURE TO PAY TAXES - 1991
AMENDMENT -
2011
AMENDMENT -
2010
AMENDMENT - 2010
AMENDMENT - 2008
AMENDMENT - 2002
AMENDMENT - 2001
AMENDMENT - 2000
|
|
UCC
(Uniform Commercial Code)
|
No
found.
|
|
OFAC
Sanctions List Search
|
The company is not in the OFAC list.
|
Summary
|
|
Summary
|
Founded in 1983, Sabinsa Corporation manufactures,
supplies, and markets herbal extracts, cosmeceuticals, minerals, dietary supplements,
and specialty fine chemicals for nutritional, cosmetic, pharmaceutical, and
food industries worldwide.
The company has approximately 47 full-time
employees and generates an estimated USD 34.2 million in annual revenue.
It mainly imports from Dubai and India, and
exports worldwide, operating within national and international markets.
This has been an ACTIVE company incorporated in NEW JERSEY in 1983.
|
Risk
Information
|
|
Debts
|
Controlled
|
|
Payments
|
Regular
|
|
Cash
Flow
|
Normal
|
|
State
|
REINSTATED
FOR TAXES
|
Interview
|
|
First
Name
|
NA
|
|
Position
|
Operator
|
|
Comments
|
The person contacted refused to provide any information about the
company if the name of the client was not given to him.
He did not tell us his name.
|
|
|
Currency
|
Unit
|
Indian Rupees
|
|
US Dollar
|
1
|
INR 64.93
|
|
UK Pound
|
1
|
INR 91.50
|
|
Euro
|
1
|
INR 79.69
|
|
US Dollar
|
1
|
INR 64.93
|
Note :
Above are approximate rates obtained from sources believed to be correct
|
Analysis Done by
:
|
PRA
|
|
|
|
|
Report Prepared
by :
|
TPT
|
|
Credit Rating
|
Explanation
|
Rating Comments
|
|
A++
|
Minimum Risk
|
Business dealings permissible with minimum
risk of default
|
|
A+
|
Low Risk
|
Business dealings permissible with low
risk of default
|
|
A
|
Acceptable Risk
|
Business dealings permissible with
moderate risk of default
|
|
B
|
Medium Risk
|
Business dealings permissible on a regular
monitoring basis
|
|
C
|
Medium High Risk
|
Business dealings permissible preferably
on secured basis
|
|
D
|
High Risk
|
Business dealing not recommended or on
secured terms only
|
|
NB
|
New Business
|
No recommendation can be done due to
business in infancy stage
|
|
NT
|
No Trace
|
No recommendation can be done as the
business is not traceable
|
NB is stated where there is insufficient information to facilitate
rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.
|
|
